Evidence Hub

Racial and ethnic disparities in US neuroendocrine tumor clinical trial enrollment over the past quarter century

X. Zheng, Akshee Batra, Joseph White, Aman Chauhan

Journal of Clinical Oncology, 2025

5,020 participants · 1 citation

Abstract

e16353

Background:

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms originating from neuroendocrine cells, with considerable variation in behavior and clinical presentation. The rising incidence of NETs has driven advancements in drug development; however, it remains unclear whether all demographic groups have equal access to novel therapeutic trials. Previous oncologic epidemiological studies have identified race-specific disparities in overall and disease-specific survival. This study aimed to assess whether similar racial and ethnic disparities exist in the enrollment of patients in NET clinical trials.

Methods:

We collected data from all completed NET clinical trials involving adult patients conducted in the United States over the past 25 years (1/1/2000 to 1/1/2025) as reported on clinicaltrials.gov. Therapeutic interventional trials were included while observational, non-interventional or non-therapeutic trials were excluded. Key study variables included race, ethnicity, sex, tumor type, and year of study. To assess enrollment patterns, we calculated the enrollment ratio for each racial and ethnic group, defined as the percentage of enrollees from each group divided by their proportion among the overall NET patient population.

Results:

We analyzed 64 NET trials, comprising 5,020 participants total. The gender distribution was similar, with 2,455 women and 2,565 men. Racial demographic data were reported in 60.9% (39/64) of the trials, while ethnicity…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free